Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

UCB’s BIMZELX (bimekizumab) receives expedited acceptance from Scottish Medicines Consortium (SMC) for the treatment of plaque psoriasis

FirstWordPharmaNovember 10, 2021

Tag: bimekizumab , SMC , plaque psoriasis

PharmaSources Customer Service